Minute Insight: Mainz Biomed Shows Off New Colorectal Cancer Diagnostic Test Data

The company’s ColoAlert mRNA-based diagnostic has proven similarly efficacious to colonoscopy, while outperforming competing blood/stool-based diagnostics.

Minute Insight
• Source: Citeline/Alamy

German diagnostics developer, Mainz Biomed, has debuted top-line data from the ColoFuture study of its colorectal cancer diagnostic, ColoAlert.

ColoFuture enrolled over 600 patients from cancer centers in Germany, Norway, and Denmark who either were receiving a colonoscopy or had been diagnosed with colorectal adenocarcinoma but had not yet...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diagnostics

More from Device Area